No Benefit for Stent Versus Medical Therapy in Stable CAD
March 01, 2012
Kathleen Stergiopoulos, M.D., Ph.D., and David L. Brown, M.D., of the Stony Brook University Medical Center in New York, conducted a meta-analysis of eight prospective randomized clinical trials identified from the literature and involving 7,229 patients who underwent either initial coronary stent implantation or medical therapy for treatment of stable CAD. The effect of each intervention on the mortality rate and incidence of nonfatal myocardial infarction, unplanned revascularization, and persistent angina was investigated.
The researchers found that the respective event rates for death after an average 4.3-year follow-up period were 8.9 percent with stent implantation and 9.1 percent with medical therapy (odds ratio [OR], 0.98; 95 percent confidence interval [CI], 0.84 to 1.16). The incidence of nonfatal myocardial infarction was 8.9 and 8.1 percent for stent implantation and medical therapy, respectively (OR 1.12; 95 percent CI, 0.93 to 1.34). Rates of unplanned revascularization (21 and 34 percent, respectively; OR, 0.78; 95 percent CI, 0.57 to 1.06) and persistent angina (29 and 33 percent, respectively; OR, 0.80; 95 percent CI, 0.60 to 1.05) were also similar between the two intervention groups.
"Initial stent implantation for stable CAD shows no evidence of benefit compared with initial medical therapy for prevention of death, nonfatal myocardial infarction, unplanned revascularization, or angina," the authors write.
While the US Preventive Services Task Force does not recommend screening for hepatitis B virus infection in asymptomatic persons in the general population, a recent update focuses on identifying those who are high risk and should be screened.
The Ebola outbreak in West Africa continues to expand and around the world researchers are striving to learn more about the disease and how to stop it to ensure that any future outbreaks of the virus are not nearly as severe.
More than 90% of children 19 to 35 months of age are getting the vaccines that prevent measles, mumps, and rubella; polio; hepatitis B; and varicella, according to the US Centers for Disease Control and Prevention. The new findings were published in the Aug. 29 issue of the CDC's Morbidity and Mortality Weekly Report.